Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

In SMA, regulatory filings for high-dose nusinersen have now been accepted ... So the total commercial return for any one molecule today is not what it was even five years ago.

The company's $2 billion-a-year medicine for the neurological disorder spinal muscular atrophy (SMA) – Spinraza (nusinersen ... to try to find small-molecule drugs that could modulate ...

Spinraza treatment does not lead to significant kidney dysfunction in SMA patients with types 1 and 2, a safety and efficacy ...

In addition to launching TRYNGOLZA, we are pleased that higher dose Nusinersen is one step closer to the market with the recent FDA and EMA acceptances of Biogen's regulatory submissions.

Good morning. My name is Jennifer, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and ...